Neurontin, Rebetol Generics Could Be Affected By “Shared Exclusivity” Ruling
Executive Summary
A federal court decision invalidating FDA's "shared exclusivity" policy for first-to-file ANDAs poses another potential complication to the launch of generic versions of Pfizer's Neurontin (gabapentin)
You may also be interested in...
Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol
Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol
“Shared Exclusivity” Could Apply To Eight First-Time Generics, FDA Says
At least eight first-time ANDA approvals over the next two years could require a determination of whether 180-day "shared exclusivity" should be awarded, FDA says in a court filing